Drug Trial Radar · NCT05667649
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Aug 14, 2023
Primary completion
Jun 25, 2026
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- Regeneration Biomedical, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
Conditions
- Alzheimer Disease
Interventions
RB-ADSCBiological
Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of RB-ADSC treatment in study participants with ADTime frame: up to 28 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.